Sarepta Therapeutics


ATLANTA, GA – – (Globe Newswire – April 14, 2023) – – Holzer & Holzer, LLC is investigating whether Sarepta Therapeutics, Inc. (“Sarepta Therapeutics” or the “Company”) (NASDAQ: SRPT) complied with federal securities laws.  On March 16, 2023, Sarepta Therapeutics announced that “at its late cycle meeting for the SRP-9001 (delandistrogene moxeparvovec) biologics license application (BLA), the U.S. Food and Drug Administration’s Office of Therapeutics (OTP) has determined that an advisory committee meeting will be held for SRP-9001 in advance of the May 29, 2023 regulatory action date.” Following this announcement, the price of the Company’s stock dropped.

If you purchased Sarepta Therapeutics stock and suffered a loss on that investment, you are encouraged to contact Marshall Dees, Esq. at or Joshua Karr, Esq. at, call our toll-free number at (888) 508-6832, or visit our website at to discuss your legal rights.


Registration Deadline

Lead Plaintiff Deadline Has Passed

Submit Your Information

Shares Purchased(Required)
Date of Shares Purchased
Number of Shares Acquired
Acquisition Price Per Share
Shares Sold
Date of Shares Sold
Number of Shares Sold
Selling Price Per Share